comparemela.com

Latest Breaking News On - Capsida biotherapeutics inc - Page 3 : comparemela.com

CRISPR Therapeutics (CRSP) and Capsida Biotherapeutics Announce Pact to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich s Ataxia

CRISPR Therapeutics (CRSP) and Capsida Biotherapeutics Announce Pact to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich s Ataxia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Capsida Biotherapeutics Debuts with $140 Million of Capital for its AAV Gene Therapies | Rothwell, Figg, Ernst & Manbeck, P C

To embed, copy and paste the code into your website or blog: Capsida Biotherapeutics Inc. a  Thousand Oaks, CA-based emerging biotechnology company recently emerged from stealth mode with $ 140 million in start-up capital. Capsida secured a $50 million Series A commitment from Versant Ventures and Westlake Village BioPartners, and a multi-year strategic collaboration and option agreement with AbbVie that provides $90 million in up front and equity investment capital in addition to potential future option, development, and commercial milestone payments. Capsida is using an adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for both CNS and non-CNS diseases. The AAV engineering platform generates capsids optimized to target specific tissues and cells in the disease organ while limiting transduction of tissues and cells not relevant to the target disease. The platform uses machine learning, structural biology, non-human p

Capsida Biotherapeutics Raises $140M in Series A Funding

Capsida Biotherapeutics Inc., a Thousand Oaks, CA-based biotechnology company using an adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases, raised $140m in Series A funding. Backers included Versant Ventures and Westlake Village BioPartners, which together provided $50m. Capsida also announced a multi-year strategic collaboration and option agreement with AbbVie that provides $90m in up front and equity investment capital in addition to potential future option, development and commercial milestone payments. The collaboration is aimed at developing targeted gene therapies for three programs in serious neurodegenerative diseases. Led by Robert Cuddihy, M.D., chief executive officer, Capsida provides an AAV engineering platform that generates capsids optimized to target specific tissue types and limits transduction of tissues and cell types that are not relevant to the target disease, allo

Capsida Biotherapeutics Debuts with $140 Million of Capital

Capsida Biotherapeutics Debuts with $140 Million of Capital - Versant, Westlake Village BioPartners launch next-generation gene therapy company with $50 million Series A - - Collaboration with AbbVie provides $90 million in up front and equity investment capital to create tissue-targeted gene therapies for three CNS disease targets - News provided by Share this article Share this article THOUSAND OAKS, Calif., April 29, 2021 /PRNewswire/ Versant Ventures and Westlake Village BioPartners today announced the emergence from stealth mode of Capsida Biotherapeutics Inc., a biotechnology company using an adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases. In addition to a $50 million Series A commitment from the two firms, Capsida also announced a multi-year strategic collaboration and option agreement with AbbVie that provides $90 million in up front and equity investment capital in addit

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.